PUBLIC SUBMISSION |
As
of: 11/4/20
9:39 AM |
Docket:
CDC-2020-0064
Colorectal
Cancer Control Program (CRCCP) Monitoring Activities
Comment
On: CDC-2020-0064-0001
Colorectal
Cancer Control Program (CRCCP) Monitoring Activities 2020-12244
Document:
CDC-2020-0064-0002
Comment
from (Anonymous Anonymous)
Submitter Information
Name: Anonymous Anonymous
General Comment
Colorectal
cancer is the second leading cause of cancer death in the United
States among men and women. So far in 2020, there are 53,200
estimated deaths from colorectal cancer (National Colorectal Cancer
Roundtable, 2020). Screening is reliably effective and can help
reduce those numbers to diagnose at an earlier stage when treatment
can often lead to a cure. The United States Preventative Services
Task Force (USPSTF) recommends screening for colorectal cancer for
adults of average risk between the ages of 50 and 75 years old
(Centers for Disease Control and Prevention, 2020). It is noted that
one in three adults do not get the recommended screening, regardless
if they have insurance (National Colorectal Cancer Roundtable, 2020).
The Centers for Disease Control and Prevention's program, called
Colorectal Cancer Control Program (CRCCP), has a purpose to implement
evidence-based interventions and other supporting strategies in
partnership with health systems to provide an increase in screening.
The program focuses on improving screening rates within a health
system, geographic area, or group most affected and in need (Centers
for Disease Control and Prevention, 2020). The CCRCP uses strategies
such as provider assessment and feedback, provider reminders, patient
reminders, and removing structural barriers for patients in
coordination with different health systems (Centers for Disease
Control and Prevention, 2020).
In regards to their
proposed project, it is feasible to revise the program's monitoring
activities including a revised annual grantee survey instrument, a
revised clinic-level data collection instrument, and a new
awardee-level quarterly program update. The program has been shown to
have great success after three years of implementation. For example,
30 awardees have worked with 679 clinics in 221 health systems,
reaching 5,436 health care providers and 1,135,719 patients between
the ages of 50 to 70 years old (Centers for Disease Control and
Prevention, 2020). The longer the clinic participates in the CRCCP,
the greater increase from baseline in their colorectal screening
rates. It has been shown that after three years, screening rates
increased 10.1 percentage points (Centers for Disease Control and
Prevention, 2020). The evidence is convincing to show the program is
effective. Expanding and revising the program will lead to better
screening rates among the impacted age population. Even though, there
is a request for approval from the Office of Management and Budget,
money is saved in several other areas. For example, patients' lost
wages are reduced and employers have lower health care costs, lower
absenteeism, and lower hiring and training new employee costs. For
insurers, high costs associated with colorectal cancer treatment are
avoided (Centers for Disease Control and Prevention, 2020). Those
patients included in the program are positively impacted with the
implementation of this program. Revising the program allows for
expansion to continue data collection and to increase screening
rates. This can ultimately lead to earlier treatment and decrease the
cancer death rate. Colorectal screening is an important aspect of
health promotion, and the program should be continued further in
order to improve the lack of screening in the United
States.
References
Centers for Disease Control
and Prevention. (2020, February). Colorectal cancer control program
(CRCCP).
https://www.cdc.gov/cancer/crccp/about.htm
National
Colorectal Cancer Roundtable. (2020). Data & progress: Colorectal
cancer is a major public health
problem.
https://nccrt.org/data-progress/
CDC Response
CDC provided a courtesy reply. The Submitter’s comment provides support for the Colorectal Cancer Control Program and updated monitoring activities; however, it is non-substantive as it does not affect this information request or burden. The comment was shared with relevant staff in CDC’s Division of Cancer Prevention and Control.
PUBLIC SUBMISSION |
As
of: 11/4/20
9:42 AM |
Docket:
CDC-2020-0064
Colorectal
Cancer Control Program (CRCCP) Monitoring Activities
Comment
On: CDC-2020-0064-0001
Colorectal
Cancer Control Program (CRCCP) Monitoring Activities 2020-12244
Document:
CDC-2020-0064-0003
Comment
from (information excluded for Clinical Content)
Submitter Information
Name: information excluded for Clinical Content
General Comment
95% of caid and care spending may be unnecessary. Proactive payment assurance to cover the operating costs and salaries of eligible and perhaps all providers and provider entities may be required. There are 12 factors, which become 20 and then 50 factors, all of which are required in every disease and detrimental behavior. These are being omitted from care. The estimates of first known ability to manage these is 1878. The number of unnecessary instances of abated vital being including the 1918 and 2020 pandemics, is more than 300,000,000, in the US alone. Review the statistical and actuarial information attached in this submittal.
Attachments
Health Industry Insight, Ideation, Visualization and Intimacy
Focus on Homocysteine, Health Industry Insight, Ideation, Visualization an Intimacy
lessons of Covid
Pregnenolone, Regenerative and Original Plasticity, as well as Choline Kinase Management
Health Industry, simplified insight, ideation, intimacy lists
Quick reference, Diagnostic, Analytic and therapeutics
Pandemics, an example of opportunity and essentiality ofmitigatingallowedInadequacyRevised
Redacted Analysis of Lysophospholipid and Cardiolipin Acyl Transferase
Redacted Analysis of Phospolipase and Diesterases
Redacted Analysis of Phospolipids, Phospholipidiesterases and Acyltransferase
Redacted Clinical Indicator Matrix and Worksheet
Redacted Environmental Survey, Translating Environment Factors into Clinical Indicators
Redacted Environment and Safeness Survey
Redacted Summary of Aldehyde Dehydrogenases, and NAD to NADH Balance
Redacted Clinical Indicator Therapeutic Map
Redacted Foundational Development Pathways
CDC Response
CDC provided a courtesy reply. The Submitter’s comment is non-substantive as it is not relevant to the Colorectal Cancer Control Program, or the design and implementation of this information collection under consideration.
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | Still-LeMelle, Terri (CDC/DDNID/NCCDPHP/OD) |
File Modified | 0000-00-00 |
File Created | 2021-01-13 |